Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-FHAB, the mouse version of SON‑1010,...